The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1482
November 23, 2015
View Complete Issue         Table of Contents 2019 
Idarucizumab (Praxbind) - An Antidote for Dabigatran
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Idarucizumab (Praxbind) - An Antidote for Dabigatran
November 23, 2015 (Issue: 1482)
The FDA has approved idarucizumab (Praxbind – Boehringer Ingelheim) for urgent reversal of the anticoagulant effect of the direct thrombin inhibitor dabigatran etexilate (Pradaxa). Idarucizumab is the first specific reversal agent to become...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Idarucizumab (Praxbind) - An Antidote for Dabigatran
Article code: 1482a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.